종목/BICX
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company offers a substance use disorder recovery program, Beat Addiction Recovery, which includes cognitive behavioral therapy modules, peer support through a mobile application, and medication prescription from an independent treating physician; and the UnCraveRx weight loss management program, a medication-assisted weight loss program that includes access to concierge on-demand wellness specialists. It also develops BICX101, an injectable and implantable naltrexone product; BICX102, a long-acting naltrexone implant that can last several months for opioid dependence and alcohol use disorders; and BICX104, a biodegradable, long-acting subcutaneous pellet of naltrexone for the treatment of opioid use disorder. The company licenses and distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. was founded in 2009 and is based in Anaheim, California.
| 발표일 | 분기 | EPS 예상 | EPS 실제 | Surprise | 매출 실제 | 발표 직후 반응 |
|---|---|---|---|---|---|---|
| 3월 31일 (화) | 2025 Q4 | $-0.06 | — | — | — | • 0.0% |
| UNH | 유나이티드헬스 | 364B | +8.9% | 75% (3/4) |
| MRK | 머크 | 281B | +16.0% | 100% (4/4) |
애널리스트 의견이 수집되지 않았습니다.